Latest evidence on gout management: What the clinician needs to know

Therapeutic Advances in Chronic Disease

Volumn 3, Issue 6, 2012, Pages 271-286

  Burns, Christopher M ^a   Wortmann, Robert L ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Febuxostat; Gout; Hyperuricemia; Inflammasome; Interleukin 1; Pegloticase; Uric acid

Indexed keywords

ALLOPURINOL; ARACLYST; ARHALOFENATE; BENZBROMARONE; CANAKINUMAB; CELECOXIB; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; FEBUXOSTAT; GLUCOCORTICOID; INDOMETACIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LESINURAD; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PEGLOTICASE; PLACEBO; PREDNISONE; PROBENECID; RASBURICASE; RDEA 3170; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SULFINPYRAZONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URATE; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ALOPECIA; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; AXONAL NEUROMYOPATHY; BONE MARROW SUPPRESSION; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DIZZINESS; DRESS SYNDROME; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; ECCHYMOSIS; EOSINOPHILIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GOUT; GRANULOMATOUS HEPATITIS; HEPATITIS; HUMAN; HYPERURICEMIA; INFECTION; INFUSION RELATED REACTION; JAUNDICE; KIDNEY FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROLITHIASIS; NEUROMUSCULAR DISEASE; NONHUMAN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RASH; REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SARCOIDOSIS; SIDE EFFECT; SINGLE DRUG DOSE; THORAX PAIN; THYROID FUNCTION TEST; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; VASCULITIS; VOMITING;

EID: 84875539662     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622312462056     Document Type: Review

References (85)

1. Anzai N. Ichida K. Jutabha P. Kimura T. Babu E. Jin C.J. et al. (2008) Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv 1 (SLC2A9) in humans. J Biol Chem 283: 26834–26838.
2. Baraf H. Becker M. Edwards N. Gutierrez-Urena S. Sundy J. Treadwell E. et al. (2008 a) Tophus response to pegloticase (PGL) therapy: pooled results from GOUT 1 and GOUT2, PGL phase 3 randomized, double blind, placebo-controlled trials. Arthritis Rheum 58: S176.
3. Baraf H. Matsumoto A. Maroli A. Waltrip R. (2008 b) Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum 58: 3632–3634.
4. Becker M. Schumacher H. Espinoza L. Wells A. MacDonald P. Lioyd E. et al. (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12: R63.
5. Becker M. Schumacher H. MacDonald P. Lloyd E. Lademacher C. (2009) Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 36: 1273–1282.
6. Becker M. Schumacher H. Wortmann R. MacDonald P. Eustace D. Palo W. et al. (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353: 2450–2461.
7. Becker M. Schumacher H. Wortmann R. MacDonald P. Lloyd E. Joseph-Ridge N. et al. (2006) Allopurinol intolerant patients treated with febuxostat for 4 years. Arthritis Rheum 54: S646.
8. Becker M. Treadwell E. Baraf H. Edwards N. Gutierrez-Urena S. Sundy J. et al. (2008) Immunoreactivity and clinical response to pegloticase (PGL): pooled data from GOUT 1 and GOUT2, PGL phase 3 randomized, double blind, placebo-controlled trials. Arthritis Rheum 58: S880.
9. Borstad G. Bryant L. Abel M. Scroggle D. Harris M. Alloway J. (2004) Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 31: 2429–2432.
10. Bree A. Phillips K. Benson M. Dower K. Shen M. Lee K. et al. (2011) Pharmacological inhibition of interleukin-1 receptor-associated kinase-4 reduces inflammation in a murine model of gout and is consistent with IL-1 signaling blockade. Arthritis Rheum 63(Suppl. 10): 1621.
11. Burns C. Wortmann R. (2011) Gout therapeutics: new drugs for an old disease. Lancet 377: 165–177.
12. Burns C. Wortmann R. (2012) Clinical features and treatment of gout. In Ed. Firestein G. (ed.), Kelley's Textbook of Rheumatology, 9th edn. New York: W.B. Saunders.
13. Chattopadhyay I. Shetty H. Routledge P. Jeffery J. (2001) Colchicine induced rhabdomyolysis. Postgrad Med J 77: 191–192.
14. Chen C. Shi Y. Hearn A. Fitzgerald K. Golenbock D. Reed G. et al. (2006) MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 116: 2262–2271.
15. Choi H. (2010) A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol 22: 165–172.
16. Choi H. Atkinson K. Karlson E. Willett W. Curhan G. (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363: 1277–1281.
17. Clive D. (2000) Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 11: 974–979.
18. Cornelis S. Kersse K. Festjens N. Lamkanfi M. Vandenabeele P. (2007) Inflammatory caspases: targets for novel therapies. Curr Pharm Des 13: 367–385.
19. Dalbeth N. McQueen F.M. (2009) Use of imaging to evaluate gout and other crystal deposition disorders. Curr Opin Rheumatol 21: 124–131.
20. Dalbeth N. Merriman T. (2009) Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout. Rheumatology 48: 222–226.
21. Dalbeth N. Stamp L. (2007) Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 20: 391–395.
22. Di Giovine F. Malawista S. Nuki G. Duff G. (1987) Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL-1. J Immunol 138: 3213–3218.
23. Dessein P. Shipton E. Stanwix A. Joffe B. Ramokgadi J. (2000) Beneficial effects of weight loss associated with moderate calorie / carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: A pilot study. Ann Rheum Dis 59: 539–543.
24. Endou H. Anzai N. (2008) Urate transport across the apical membrane of renal proximal tubules. Nucleosides Nucleotides Nucleic Acids 27: 578–584.
25. Enomoto A. Kimura H. Chairoungdu A. Shigeta Y. Jutabha P. Cha S. et al. (2002) Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417: 447–452.
26. Fam A. Dunne S. Iazzetta J. Paton T. (2001) Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 44: 231–238.
27. Goldfarb E. Smythe C. (2007) Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout. Arthritis Rheum 9: 414–423.
28. Gopal C. Saha G. Karpf D. Choi Y. Roberts B. (2011) Arhalofenate, a potential novel treatment for hyperuricemia, with or without metabolic co-morbidities, in patients with gout: meta-analysis of urate lowering in four phase 2 studies in type 2 diabetes. Arthritis Rheum 63(Suppl. 10): 2584.
29. Guard G. Dostert C. Staehli F. Cabalzar K. Castillo R. Tardivel A. et al. (2009) T cells dampen innate immune responses through inhibition of NLRP 1 and NLRP 3 inflammasomes. Nature 460: 270–273.
30. Hamburger S. Lipsky P. Simon L. (2010) Safety and efficacy of long-term pegloticase (KRYSTEXXA™) treatment in adult patients with chronic gout refractory to conventional therapy. Arthritis Rheum 62(Suppl. 10): L12.
31. Hande K. Noone R. Stone W. (1984) Severe allopurinol toxicity. Am J Med 76: 47–56.
32. Hensch P. (1936) The diagnosis of gout and gouty arthritis. J Lab Clin Med 220: 48–55.
33. Kim K. Schumacher R. Hunsche E. Wertheimer A. Kong S. (2003) A literature review of the epidemiology and treatment of acute gout. Clin Ther 25: 1593–1617.
34. Kim S. Guevara J. Kim K. Choi H. Heitjan D. Albert D. (2010) Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 62: 170–180.
35. Kingsbury S. Conaghan P. McDermott M. (2011) The role of the NLRP 3 inflammasome in gout. J Inflamm Res 4: 39–49.
36. Lee M. Graham G. Williams K. Day R. (2008) A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 31: 643–665.
37. Liu-Bryan R. Scott P. Sydlaske A. Rose D. Terkeltaub R. (2005) Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 52: 2936–2946.
38. Li-Yu J. Clayburne G. Sieck M. Beutler A. Rull M. Eisner E. et al. (2001) Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 28: 577–580.
39. Malawista S. de Boisfleury A. Naccache P. (2011) Inflammatory gout: observations over a half-century. FASEB J 25: 4073–4078.
40. Martin W. Walton M. Harper J. (2009) Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum 60: 281–289.
41. Martinon F. Petrilli V. Mayor A. Tardivel A. Tschopp J. (2006) Gout-associated uric acid crystals activate the NALP 3 inflammasome. Nature 440: 237–241.
42. Mitroulis M. Skendros P. Ritis K. (2010) Targeting IL-1β in disease; the expanding role of NLRP 3 inflammasome. Eur J Int Med 21: 157–163.
43. Molad Y. (2002) Update on colchicine and its mechanism of action. Curr Rheum Rep 4: 252–256.
44. Pascual E. Battle-Gualda E. Martinez A. Rosas J. Vela P. (1999) Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 131: 756–759.
45. Paulus H. Schlosstein L. Godfrey R. Klinenberg J. Bluestone R. (1974) Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 17: 609–614.
46. Perez-Ruiz F. Alonso-Ruiz A. Calabozo M. Herrero-Beites A. Garcia-Erauskin G. Ruiz-Lucea E. (1998) Efficacy of allopurinol and benzbromarone for the control of hyperuricemia: A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57: 545–549.
47. Perez-Ruiz F. Calabozo C. Herrero-Beites A. Garcia-Erauskin G. Pijoan J. (2000) Improvement in renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 86: 287–291.
48. Perez-Ruiz F. Calabozo M. Pijoan J. Herrero-Beites A. Ruibal A. (2002) Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Care Res 47: 356–360.
49. Rho Y. Zhu Y. Choi H. (2011) The epidemiology of uric acid and fructose. Semin Nephrol 31: 410–419.
50. Richette P. Briere C. Honene-Claviert V. Loeuille D. Bardin T. (2007) Rasburicase for tophaceous gout not treatable with allopurinol: An exploratory study. J Rheumatol 34: 1093–1098.
51. Roddy E. Zhang W. Doherty M. (2007) The changing epidemiology of gout. Nat Clin Pract Rheumatol 3: 443–449.
52. Schlesinger N. de Meulemeester M. Pikhlak A. Yücel A. Richard D. Murphy V. et al. (2011 a) Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 13: R53.
53. Schlesinger N. Mysler E. Lin H. de Meulemeester M. Rovensky J. Arulmani U. et al. (2011 b) Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 70: 1264–1271.
54. Schumacher H. Becker M. Lloyd E. MacDonald P. Lademacher C. (2009) Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology 48: 188–194.
55. Schumacher H. Becker M. Wortmann R. MacDonald P. Hunt B. Streit J. et al. (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel group trial. Arthritis Rheum 59: 1540–1548.
56. Schumacher H. Sundy J. Terkeltaub R. Knapp H. Mellis S. Stahl N. et al. (2012) Rilonacept (Interleukin-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 64: 876–884.
57. Scott P. Ma H. Viriyakosol S. Terkeltaub R. Liu-Bryan R. (2006) Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol 177: 6370–6378.
58. Sherman M. Saifer M. Perez-Ruiz F. (2008) PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 60: 59–68.
59. Simkin P. (2003) New standards for uric acid excretion: evidence for an inducible transporter. Arthritis Care Res 49: 735–736.
60. Siu Y. Leung K. Tong M. Kwan T. (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid. Am J Kidney Dis 47: 51–59.
61. So A. de Meulemeester M. Pikhlak A. Yücel A. Richard D. Murphy V. et al. (2010) Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis. Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 62: 3064–3076.
62. So A. de Smedt T. Revaz S. Tschopp J. (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9: R28.
63. Stamp L. Taylor W. Jones P. Dockerty J. Drake J. Frampton C. et al. (2011) Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed nomogram for safe starting dosing of allopurinol. Arthritis Rheum 63(Suppl. 10): 25.
64. Sundy J. Baraf H. Gutierrez-Urena S. Yood R. Huang B. Maroli A. et al. (2009) Chronic use of pegloticase: study and efficacy update. Arthritis Rheum 60(Suppl. 10): 1113.
65. Sundy J. Baraf H. Yood R. Edwards N. Gutierrez-Urena S. Treadwell E. et al. (2011) Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306: 711–720.
66. Sundy J. Becker M. Baraf H. Barkhuizen A. Moreland L. Huang W. et al. (2008) Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment failure gout. Arthritis Rheum 58: 2882–2891.
67. Sundy J. Ganson N. Kelly S. Scarlett E. Rehrig C. Huang W. et al. (2007) Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 56: 1021–1028.
68. Tan P. Hyndman D. Miner J.N. (2011) Identification of specific amino acids in the uric acid transporter URAT 1 required for uricosuric-mediated inhibition. Arthritis Rheum 63(Suppl. 10): 1592.
69. Terkeltaub R. Furst D. Bennett K. Kook K. Crockett R. Davis M. (2010) High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62: 1060–1068.
70. Terkeltaub R. Sundy J. Schumacher H. Murphy F. Bookbinder S. Biedermann S. et al. (2009) The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study. Ann Rheum Dis 68: 1613–1617.
71. Thiele R. Schlesinger N. (2007) Diagnosis of gout by ultrasound. Rheumatology 46: 1116–1121.
72. Torres R. MacDonald L. Croll S. Reinhardt J. Dore A. Stevens S. et al. (2009) Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 68: 1602–1608.
73. Wallace S. Bernstein D. Diamond H. (1967) Diagnostic value of the colchicine therapeutic trial. JAMA 199: 525–528.
74. Wallace S. Robinson H. Masi A. Decker J. McCarty D. Yu T. (1977) Preliminary criteria for the classification of acute arthritis of primary gout. Arthritis Rheum 20: 895–900.
75. Wright D. Sundy J. Rosario-Jansen T. (2009) Routine serum uric acid (SUA) monitoring predicts antibody-mediated loss of response and infusion reaction risk during pegloticase therapy. Arthritis Rheum 60(Suppl. 10): 1104.
76. Wright S. Filippucci E. McVeigh C. Grey A. McCarron M. Grassi W. et al. (2007) High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study. Ann Rheum Dis 66: 859–864.
77. Wortmann R. (1998) The treatment of gout: The use of an analogy. Am J Med 105: 513–514.
78. Wu X. Lee C. Muzny D. Caskey C. (1989) Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci USA 86: 9412–9416.
79. Wurzner G. Gester J. Chiolero A. Maillard M. Fallab-Stubi C. Brunner H. et al. (2001) Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 19: 1855–1860.
80. Wyngaarden J. Kelley W. (1976) Disposition of uric acid in primary gout. In: Ed. Wyngaarden J. Kelley W. (eds), Gout and Hyperuricemia. New York: Grune & Stratton.
81. Yamamoto T. Moriwaki Y. Tukahashi S. Tsutsumi Z. Hada T. (2001) Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol 28: 2294–2297.
82. Yu T. Gutman A. (1961) Efficacy of colchicine prophylaxis: Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med 55: 179–192.
83. Yu T. Gutman A. (1967) Uric acid nephrolithiasis in gout: Predisposing factors. Ann Intern Med 67: 1133–1148.
84. Zhang W. Doherty M. Pascual E. Bardin T. Barskova V. Conaghan P. et al. (2006 a) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 65: 1301–1311.
85. Zhang W. Doherty M. Pascual E. Barskova V. Guerne P. Jansen T. et al. (2006 b) EULAR evidence based recommendations for gout. Part II: Management. Ann Rheum Dis 65: 1312–1324.